title: [Pharmacology of bone resorption inhibitor].
abstract: Currently, bone resorption inhibitor is mainly used for osteoporosis. A number of these agents have been developed. These pharmacological action are various. Bisphosphonate inhibit functions of the osteoclasts by inducing apoptosis. On the one hand, RANK-ligand inhibitor and selective estrogen receptor modulator inhibit formation of osteoclasts. It is important to understand these pharmacological action for the selection of the appropriate medicine.
authors.forename: Kunitaka
authors.initials: K
authors.lastname: Menuki
authors.forename: Akinori
authors.initials: A
authors.lastname: Sakai
mesh_terms: D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D001862:Bone Resorption / Q000188:drug therapy*; D002116:Calcitonin / Q000378:metabolism; D004164:Diphosphonates / Q000627:therapeutic use; D006801:Humans; D010024:Osteoporosis / Q000188:drug therapy; D053245:RANK Ligand / Q000378:metabolism
chemical_list: D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D053245:RANK Ligand; D002116:Calcitonin